Evidence map›Paper›PMID 41390175›Full record

ArticleGut2026

CD177

Jiayan Yan, Ao Huang, Shiyu Zhang, Na Yao, Junfeng Huang, Zhifeng Jiang, Jiayi Wang, Feiyu Chen, Qichao Yu, Jianwen Cheng and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Jiayan Yan *Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-1751-7842
Ao Huang *Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Shiyu Zhang *Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9021-3875
Na Yao *Laboratory of Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Junfeng Huang *Liver Surgery Intensive Care Unit, Department of Intensive Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhifeng JiangDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiayi WangDepartment of Nephrology, Shanghai Medical Center of Kidney and Shanghai Key Laboratory of Kidney and Blood Purification, Zhongshan Hospital, Fudan University, Shanghai, China.
Feiyu ChenDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Qichao YuZhongshan-BGI Precision Medical Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianwen ChengDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Senquan ZhangDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Tianyi LiDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongshan GaoDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Runze MiaoDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shaolai ZhouDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Dongmei GaoLaboratory of Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenbin DingDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhaoyou TangDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia FanDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-5158-629X
Miguel A Esteban3DC STAR Laboratory, BGI CELL, Shenzhen, Guangdong, China.
Hans Jürgen SchlittDepartment of Surgery, University of Regensburg Medical Center, Regensburg, Germany.
Xinrong YangDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China zhou.jian@zs-hospital.sh.cn yang.xinrong@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-2716-9338
Jian ZhouDepartment of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China zhou.jian@zs-hospital.sh.cn yang.xinrong@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-2118-1117

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAssociating liver partition and portal vein ligation for staged hepatectomy (ALPPS) effectively induces rapid liver hypertrophy in patients with initially unresectable liver tumours, yet the immunological mechanisms remain unclear.

objectiveWe aim to elucidate the immune alterations and underlying mechanisms driving liver regeneration following ALPPS.

designThe cohort study included single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on remnant liver tissues from ALPPS patients. Neutrophil infiltration was validated by flow cytometry and histological analyses in the world's largest ALPPS clinical cohort and mouse ALPPS models. Functional validation, including neutrophil depletion, matrix metalloproteinase 9 (MMP9) inhibition and CD177 blockade, as well as

resultsscRNA-seq revealed substantial neutrophil infiltration following stage 1 ALPPS. Depletion of neutrophils impaired liver regeneration. Among subsets, CD177

conclusionsCD177

Indexed as

Extracellular MatrixHepatectomyHepatocyte Growth FactorIsoantigensLiver RegenerationNeutrophilsReceptors, Cell SurfaceAnimalsFemaleGPI-Linked ProteinsHumansLigationLiverMaleMatrix Metalloproteinase 9MiceCD177 protein, humanCmkor1 protein, mouseGPI-Linked ProteinsHepatocyte Growth FactorHGF protein, mouseIsoantigensMatrix Metalloproteinase 9Receptors, Cell SurfaceReceptors, CXCRHEPATOBILIARY CANCERHEPATOBILIARY SURGERYLIVER IMMUNOLOGYLIVER REGENERATION

Identifiers

PMID41390175
PMCPMC13479642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.